{"id":476416,"date":"2020-03-26T13:38:01","date_gmt":"2020-03-26T13:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476416"},"modified":"2020-03-26T13:38:01","modified_gmt":"2020-03-26T13:38:01","slug":"end-stage-renal-disease-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/end-stage-renal-disease-epidemiology-forecast-to-2030_476416.html","title":{"rendered":"End Stage Renal Disease Epidemiology Forecast to 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585222469.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"End Stage Renal Disease Epidemiology Forecast to 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585222469.jpeg\" alt=\"End Stage Renal Disease Epidemiology Forecast to 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>End Stage Renal Disease Epidemiology<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s \u201cEnd Stage Renal Disease Epidemiology Forecast to 2030\u201d report delivers an in-depth understanding of the disease, historical and forecasted End Stage Renal Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p><\/div>\n<p style=\"text-align: justify;\">DelveInsight launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-esrd-epidemiology-forecast\">End Stage Renal Disease Epidemiology Forecast to 2030<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the report:-<\/strong><\/p>\n<p style=\"text-align: justify;\">1. End-Stage Renal Disease is more common in men than in women. The prevalence of chronic renal failure between the years 2007 and 2011 was higher in women (15.1%) than in men (12.1%).<br \/> 2. About 15% of adults in the US are estimated to have chronic kidney disease. Chronic kidney disease can often be treated before it progresses to end-stage renal failure or leads to other health problems.<br \/> 3. End-Stage Renal Disease prevalence in the US in 2007 was 1,698 cases per million population. In 2007, Japan also observed relatively high prevalence, i.e., 2,060 cases per million population of End-Stage Renal Disease, which included only people receiving maintenance dialysis.<\/p>\n<p style=\"text-align: justify;\">Request for sample pages:- <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/end-stage-renal-disease-esrd-epidemiology-forecast\">https:\/\/www.delveinsight.com\/sample-request\/end-stage-renal-disease-esrd-epidemiology-forecast<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/f43d66b9f2857c69835ca808621f680f.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The End Stage Renal Disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The End Stage Renal Disease Epidemiology Report and Model provide an overview of the risk factors and global trends of End Stage Renal Disease in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight about the historical and forecasted patient pool of End Stage Renal Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Sanfilippo Syndrome<\/li>\n<li>The report provides the segmentation of the End Stage Renal Disease epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Reasons to buy<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The End Stage Renal Disease Epidemiology report will allow the user to &#8211;<\/li>\n<li>Develop business strategies by understanding the trends shaping and driving the global End Stage Renal Disease market<\/li>\n<li>Quantify patient populations in the global End Stage Renal Disease market to improve product design, pricing, and launch plans<\/li>\n<li>Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for End Stage Renal Disease therapeutics in each of the markets covered<\/li>\n<li>Understand the magnitude of End Stage Renal Disease population by its epidemiology<\/li>\n<li>The End Stage Renal Disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Request for sample pages:- <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/end-stage-renal-disease-esrd-epidemiology-forecast\">https:\/\/www.delveinsight.com\/sample-request\/end-stage-renal-disease-esrd-epidemiology-forecast<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<strong>Table of contents <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1.&nbsp;Key Insights<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of End-Stage Renal Disease (ESRD)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3.&nbsp;End-Stage Renal Disease (ESRD): Disease Background and Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">3.1.&nbsp;Introduction<\/p>\n<p style=\"text-align: justify;\">3.2.&nbsp;Sign and Symptoms<\/p>\n<p style=\"text-align: justify;\">3.3.&nbsp;Pathophysiology<\/p>\n<p style=\"text-align: justify;\">3.4.&nbsp;Risk Factors<\/p>\n<p style=\"text-align: justify;\">3.5.&nbsp;Diagnosis<\/p>\n<p style=\"text-align: justify;\"><strong>4.&nbsp;Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>5.&nbsp;Epidemiology and Patient Population<\/strong><\/p>\n<p style=\"text-align: justify;\">5.1.&nbsp;Epidemiology Key Findings<\/p>\n<p style=\"text-align: justify;\">5.2.&nbsp;Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\"><strong>5.3.&nbsp;Epidemiology Scenario: 7MM<\/strong><\/p>\n<p style=\"text-align: justify;\">5.3.1.&nbsp;End-Stage Renal Disease (ESRD) Epidemiology Scenario in the 7MM (2017- 2030)<\/p>\n<p style=\"text-align: justify;\"><strong>5.4.&nbsp;United States Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">5.4.1.&nbsp;End-Stage Renal Disease (ESRD) Epidemiology Scenario in the United States (2017- 2030)<\/p>\n<p style=\"text-align: justify;\"><strong>5.5.&nbsp;EU-5 Country-wise Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">5.5.1. Germany Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.1.1.&nbsp;End-Stage Renal Disease (ESRD) Epidemiology Scenario in Germany (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.2. France Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.2.1.&nbsp;End-Stage Renal Disease (ESRD) Epidemiology Scenario in France (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.3. Italy Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.3.1.&nbsp;End-Stage Renal Disease (ESRD) Epidemiology Scenario in Italy (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.4. Spain Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.4.1.&nbsp;End-Stage Renal Disease (ESRD) Epidemiology Scenario in Spain (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.5. United Kingdom Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.5.1.&nbsp;End-Stage Renal Disease (ESRD) Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p style=\"text-align: justify;\"><strong>5.6. Japan Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">5.6.1.&nbsp;End-Stage Renal Disease (ESRD) Epidemiology Scenario in Japan (2017- 2030)<\/p>\n<p style=\"text-align: justify;\"><strong>6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p style=\"text-align: justify;\">6.1.&nbsp;End-Stage Renal Disease (ESRD) Treatment and Management<\/p>\n<p style=\"text-align: justify;\">6.2.&nbsp;End-Stage Renal Disease (ESRD) Treatment Algorithm<\/p>\n<p style=\"text-align: justify;\"><strong>7.&nbsp;KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8.&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9.&nbsp;&nbsp;Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\">9.1.&nbsp;Bibliography<\/p>\n<p style=\"text-align: justify;\">9.2.&nbsp;Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>10.&nbsp;DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11.&nbsp;Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12.&nbsp;About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Related reports :-<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/end-stage-renal-disease-esrd-market\" target=\"_blank\">End-Stage&nbsp;Renal&nbsp;Disease&nbsp;(ESRD) Market Insight, Epidemiology and Market Forecast -2030<\/a><\/p>\n<p class=\"posttext\" style=\"text-align: justify;\">DelveInsight&#8217;s End-Stage Renal Disease (ESRD) &#8211; Market Insights, Epidemiology and Market Forecast &#8211; 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_55879.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=end-stage-renal-disease-epidemiology-forecast-to-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=end-stage-renal-disease-epidemiology-forecast-to-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>End Stage Renal Disease Epidemiology DelveInsight&#8217;s \u201cEnd Stage Renal Disease Epidemiology Forecast to 2030\u201d report delivers an in-depth understanding of the disease, historical and forecasted End Stage Renal Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/end-stage-renal-disease-epidemiology-forecast-to-2030_476416.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-476416","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=476416"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476416\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=476416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=476416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=476416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}